Alabama Clinical Trials Report — April 2026

For Alabamians considering participation in medical research, April 2026 presents a crucial window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 95 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 20 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on specific types of cancer, kidney function, and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Primary peritoneal cancer
• Acute kidney injury
• Atopic dermatitis
• Stress
• Idiopathic hypersomnia
• Anxiety
• Affective symptoms
• Advanced lung neuroendocrine tumor
• Acute respiratory distress syndrome
• Amputation, traumatic/surgery

Groundbreaking Research Launches: Obesity, Cancer, and Diagnostics

This month brings several high-profile new trials to Alabama, including significant Phase 2 and 3 studies from major pharmaceutical companies. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to advanced cancers.

• Novo Nordisk A/S is launching NCT07533175, "AMAZE 2," a Phase 3 study investigating a new medicine, NNC0487-0111, for individuals with excess body weight and Type 2 diabetes. This large trial aims to enroll 630 participants to evaluate the safety and effectiveness of this weekly injectable treatment.
• Incyte Corporation is sponsoring NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 for previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial seeks 588 participants.
• Eccogene is initiating the "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial," NCT07505303. This Phase 2 study, involving 160 participants, will assess the effect of oral ECC4703 on body weight reduction and liver fat content.
• The University of Alabama at Birmingham (UAB) is leading NCT07521657, a Phase 2 study evaluating mirdametinib alone or in combination with radiotherapy for germline and sporadic NF1-altered high-grade glioma. This trial is designed for 55 participants.
• Sano Chemicals Inc is sponsoring NCT07521137, a Phase 2a study evaluating the safety and efficacy of OCF001 intravaginal gel for women with acute vulvovaginal candidiasis, involving 36 participants.
• BioMérieux is conducting NCT07513519, a hybrid-effectiveness study on the impact of a multiplex respiratory PCR test for patients with respiratory illness in urgent care settings. This study plans to enroll 800 participants.
• Mead Johnson Nutrition is sponsoring NCT07513506, an Extensively Hydrolyzed Formula Growth Monitoring Study, comparing an investigational infant formula against a currently marketed one, with 214 participants.

April's Research Landscape: New Opportunities and Geographic Reach

This month, Alabama saw the opening of 12 new clinical trials, a slight decrease from the 18 trials that launched in March 2026. Despite this modest dip, the state continues to offer a diverse array of research opportunities, with a total of 1,205 clinical trials currently recruiting across 37 cities and 591 research sites.

The majority of new research initiatives this month are concentrated in the Birmingham metropolitan area, with 11 of the 12 new trials opening in Birmingham itself. Gardendale and Hoover each saw one new trial launch. While new trial openings are centralized, the overall research landscape remains broadly accessible across Alabama.

New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Acellular dermal matrix
• Acute respiratory infections (ARIs)
• Adult obesity
• Alveolar mucosa
• Brain fog
• Vulvovaginal candidiasis
• Chronic fatigue
• Chronic fatigue syndrome (CFS)
• Cognitive dysfunction
• Cognitive impairment

The types of interventions being studied are varied, with drug trials leading the way, accounting for 5 of the new trials. Procedure-based studies represent 3 new trials, behavioral interventions 2, and medical devices 2. There is also one new combination product trial and one other type of study.

Diverse Participation: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 12 new trials launched this month, 11 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 4 new trials are open to children, and one study is specifically designed for female participants.

For individuals without a specific medical condition, there are significant opportunities to contribute. 4 of the new trials this month are actively seeking healthy volunteers. Across Alabama, a total of 153 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Academic institutions continue to play a vital role in Alabama's research ecosystem, with the University of Alabama at Birmingham sponsoring 5 of the new trials. Industry sponsors, including Novo Nordisk A/S, Incyte Corporation, BioMérieux, Mead Johnson Nutrition, Eccogene, Occlutech International AB, and Sano Chemicals Inc, are also driving significant research efforts, accounting for 7 of the new studies this month.

As we move further into spring, the focus will likely shift towards the ongoing enrollment in these significant Phase 2 and 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Alabama.